🔎 Trials Near Me

Utama › Karsinoma Epitel Ovari › Minnesota

Kajian klinikal Karsinoma Epitel Ovari di Minnesota

7 kajian untuk Karsinoma Epitel Ovari sedang mencari peserta di lokasi di Minnesota.

Bandar di Minnesota

Teks kajian rasmi (Bahasa Inggeris)

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • University of Minnesota - Minneapolis /ID# 275718, Minneapolis
  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT06890338

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Masonic Cancer Center, University of Minnesota, Minneapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT06915025

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • Mayo Clinic (Rochester), Rochester
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  • Research Site, Minneapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 21 Jul 2026 · NCT07218809

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Minnesota Oncology Hematology PA, Minneapolis
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 2 Jul 2026 · NCT06819007

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • Mayo Clinic, Rochester
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06395519

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • SCRI - Minnesota Oncology Hematology, P.A., Minneapolis
  • University of Minnesota, Minneapolis
  • Mayo Clinic, Rochester
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 23 Dis 2025 · NCT06690775

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.